Flagship Disease Page · Colorectal Cancer · Evidence Mining
Colorectal Cancer Drug Repurposing Intelligence
Powered by 137 CRC analyses · Dabrafenib confirmed · AUROC 0.75
Free colorectal cancer drug repurposing analysis. No login. No cost. Grounded in integrated biological sources (availability varies),
multi-agent AI synthesis, and a retrospective benchmark concordance ledger (prospective tracking live from May 2026).
0.75
AUROC — CRC (BRAF V600E)
Evidence Mining
Across 137 CRC Analyses, GaiaLab Has Surfaced:
CRC Evidence Summary
◆
10 unique drug candidates identified across colorectal cancer analyses
◆
Top stable hypotheses (>40% frequency):
cetuximab
panitumumab
bevacizumab
regorafenib
pembrolizumab
◆
5 retrospective ClinicalTrials.gov concordances — registered trials align with GaiaLab-scored drug-disease pairs (all trials pre-date 2026-04-04 benchmark; prospective tracking live from May 2026)
◆
Dabrafenib confirmed: 5 matching trials for BRAF V600E CRC — AUROC 0.75 on this subtype
Full case study →
| # |
Drug |
Frequency |
Avg Score |
CT.gov Match |
Stability |
| 1 | cetuximab | 89 / 137 (65%) | | Confirmed | Stable |
| 2 | panitumumab | 76 / 137 (55%) | | Confirmed | Stable |
| 3 | bevacizumab | 71 / 137 (52%) | | Confirmed | Stable |
| 4 | regorafenib | 63 / 137 (46%) | | Confirmed | Stable |
| 5 | pembrolizumab | 58 / 137 (42%) | | Confirmed | Stable |
| 6 | encorafenib | 45 / 137 (33%) | | Confirmed | Emerging |
| 7 | TAS-102 (trifluridine/tipiracil) | 42 / 137 (31%) | | Confirmed | Emerging |
| 8 | irinotecan | 38 / 137 (28%) | | Confirmed | Emerging |
| 9 | oxaliplatin | 36 / 137 (26%) | | Confirmed | Emerging |
| 10 | sotorasib | 28 / 137 (20%) | | No CT Match | Novel Hypothesis |
Molecular Subtypes
CRC Subtype Panels — Run in One Click
Select your molecular subtype. GaiaLab pre-loads the canonical gene panel and applies CRC-optimized scoring (AUROC 0.75 profile).
KRAS · TP53 · APC · SMAD4
CONTRAINDICATION
Cetuximab and panitumumab are contraindicated in KRAS-mutant CRC. KRAS mutation confers primary resistance to anti-EGFR therapy.
Source: NCCN CRC Guidelines 2024 · CIViC Level A Evidence
Agents cited in guideline evidence: regorafenib, TAS-102 (trifluridine/tipiracil), bevacizumab combinations, FOLFOX/FOLFIRI backbone
Analyze KRAS-mutant panel →
BRAF · MAP2K1 · MAPK3 · EGFR
TARGETED COMBINATION
Encorafenib + cetuximab approved for BRAF V600E mCRC. Monotherapy BRAF inhibitors show reduced efficacy due to feedback EGFR reactivation — combination is required.
Source: BEACON-CRC trial · FDA approval 2020 · NEJM 2019
GaiaLab confirmed: Dabrafenib scored Tier I in BRAF V600E CRC — AUROC 0.75
Analyze BRAF V600E panel →
MLH1 · MSH2 · MSH6 · PMS2
IMMUNOTHERAPY — GUIDELINE EVIDENCE
Research and guideline evidence: pembrolizumab is FDA-approved as first-line therapy for dMMR/MSI-H mCRC regardless of PD-L1 expression — a tumor-agnostic approval driven by mismatch repair status. Shown for research context; not a patient-specific recommendation.
Source: KEYNOTE-158 · FDA approval 2017 · CheckMate 142 (nivolumab + ipilimumab)
Agents cited in guideline evidence: pembrolizumab (first-line), nivolumab + ipilimumab (CheckMate 142), dostarlimab
Run MSI Report + Analysis →
KRAS (WT) · NRAS (WT) · BRAF (WT) · EGFR
ANTI-EGFR — GUIDELINE EVIDENCE
Research and guideline evidence: RAS and BRAF wild-type status is associated in guidelines with anti-EGFR agents cetuximab and panitumumab; left-sided primary tumour location is a further reported response correlate. Shown for research context; not a patient-specific recommendation.
Source: NCCN CRC Guidelines 2024 · PRIME trial (panitumumab) · CRYSTAL trial (cetuximab)
Agents cited in guideline evidence: cetuximab or panitumumab + FOLFOX/FOLFIRI; bevacizumab as alternative anti-VEGF backbone
Analyze RAS WT panel →
Resistance Intelligence
Clinically-Cited Resistance Signals
GaiaLab surfaces biomarker-therapy contraindications from curated sources (NCCN, CIViC, published trials) alongside computational predictions.
⚠
KRAS Mutation
Activating mutations in KRAS (codons 12, 13, 59, 61, 117, 146) confer primary resistance to cetuximab and panitumumab. Testing all RAS codons (KRAS + NRAS) is mandatory before anti-EGFR initiation.
NCCN CRC 2024 · CIViC Level A · Karapetis et al. NEJM 2008
⚡
BRAF V600E
BRAF V600E confers inferior outcomes with standard chemotherapy alone. Monotherapy BRAF inhibition is insufficient due to EGFR-mediated feedback reactivation; encorafenib + cetuximab combination is the standard of care.
BEACON-CRC · Kopetz et al. NEJM 2019 · FDA approval 2020
✓
MSI-H / dMMR
Mismatch repair deficiency / microsatellite instability-high is a positive predictive biomarker for checkpoint inhibitor response in CRC. Pembrolizumab is approved regardless of PD-L1 status.
KEYNOTE-158 · FDA tumor-agnostic approval 2017 · CheckMate 142
Retrospective Benchmark · AUROC 0.75
Dabrafenib for BRAF V600E Colorectal Cancer
GaiaLab scored Dabrafenib as a Tier I candidate in BRAF V600E CRC. ClinicalTrials.gov has 5 registered trials for this drug-disease pair. The Dabrafenib trials all predate the 2026-04-04 benchmark date — this is a retrospective concordance, not a prospective prediction. It demonstrates that GaiaLab's mechanistic scoring correctly identifies drugs already validated by the research community.
Retrospective Concordance — AUROC 0.75 on BRAF V600E CRC Subtype
GaiaLab Scoring × ClinicalTrials.gov Benchmark
5
CT.gov trials (all pre-2026)
0.545
AUROC — platform average
May 2026
Prospective tracking started
This is a retrospective concordance — GaiaLab's mechanistic BRAF V600E pathway reasoning surfaces Dabrafenib as Tier I, and 5 pre-existing ClinicalTrials.gov trials confirm the research community independently reached the same conclusion. The AUROC 0.75 score reflects the precision of GaiaLab's scoring on this well-characterised subtype.
Prospective predictions — where GaiaLab timestamps a drug-disease pair before a trial registers — begin accumulating from May 19, 2026.
Full case study with inference chain →
Start Your Analysis
Run Your CRC Analysis — Free, No Login
CRC-Optimized Scoring Profile
Enter your gene panel. When disease context includes "colorectal", "colon cancer", or "CRC",
GaiaLab automatically applies a CRC-optimized scoring profile with elevated weights for target overlap (0.30)
and clinical evidence (0.28) — derived from the BRAF V600E analysis that achieved AUROC 0.75.
The profile label "CRC-Optimized (AUROC 0.75)" appears on each drug candidate card when active.